Publications by authors named "Hirofumi Kon"
Article Synopsis
- - The study aimed to compare the effectiveness of a new bowel preparation solution, ASC-PEG, with the standard PEG-ELS solution in patients prepping for laparoscopic surgery for colorectal cancer.
- - In a controlled trial with 173 patients, results showed ASC-PEG was similarly effective as PEG-ELS, with a high rate of "excellent" or "good" bowel preparations and less overall solution volume needed for cleansing.
- - The findings suggest ASC-PEG is a viable alternative for preoperative bowel preparation, with similar safety and tolerance levels between the two solutions.
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT.
View Article and Find Full Text PDFBackground: Dialysis patients are predisposed to severe disease and have a high mortality rate in coronavirus disease 2019 (COVID-19) due to their comorbidities and immunocompromised conditions. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to examine how long the effects of the vaccine are maintained and what factors affect antibody titers.
View Article and Find Full Text PDFAim: The aim of this retrospective study was to investigate the incidence of cardiovascular thrombotic complications after laparoscopic resection in colorectal cancer.
Methods: This study involved 2017 patients with stages 0-III colorectal cancer who underwent laparoscopic surgery at 17 Japanese hospitals between January 2010 and December 2013. We assessed the incidence of postoperative cardiovascular thrombotic and haemorrhagic complications.
Purpose: In this follow-up of the R-NAC-01 study, we assessed the long-term oncological benefit of four courses of modified leucovorin, 5-fluorouracil (FU), and oxaliplatin (mFOLFOX6) chemotherapy before rectal surgery.
Methods: In this prospective, multicenter study (UMIN 000012559) involving 11 hospitals in Japan, patients with lower rectal cancer underwent four cycles of mFOLFOX6 chemotherapy and subsequent surgery within four to six weeks. The 3-year recurrence-free survival and local recurrence rates were then reported.
Article Synopsis
- The study aimed to evaluate the safety of rectal surgery following 5-fluorouracil-leucovorin-oxaliplatin chemotherapy (FOLFOX6) in rectal cancer patients.
- Conducted across 11 Japanese hospitals, the research included 41 patients who underwent chemotherapy before surgery, with results showing manageable postoperative complications and nerve preservation in most cases.
- The findings suggest that surgery after modified FOLFOX6 chemotherapy is a viable and safe option for patients with locally advanced rectal cancer, although no patients achieved complete pathological remission.
An 80-year-old man was diagnosed with advanced gastric cancer and underwent distal gastrectomy. Although the pathological Stage of the cancer was III A, he refused adjuvant chemotherapy. One year later, CT revealed multiple liver metastases.
View Article and Find Full Text PDF